Kornitzer Capital Management Inc. KS Sells 38,935 Shares of Lantheus Holdings, Inc. $LNTH

Kornitzer Capital Management Inc. KS reduced its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 49.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 40,385 shares of the medical equipment provider’s stock after selling 38,935 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Lantheus were worth $2,688,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Hantz Financial Services Inc. boosted its stake in shares of Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 396 shares during the period. First Horizon Corp bought a new stake in shares of Lantheus in the third quarter valued at approximately $26,000. Osterweis Capital Management Inc. bought a new stake in shares of Lantheus in the second quarter valued at approximately $36,000. Farther Finance Advisors LLC boosted its stake in shares of Lantheus by 71.4% in the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 275 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Lantheus during the third quarter valued at approximately $55,000. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

LNTH has been the subject of several research analyst reports. Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Tuesday, February 24th. Wall Street Zen upgraded shares of Lantheus from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 28th. Jefferies Financial Group restated a “buy” rating and set a $110.00 price objective on shares of Lantheus in a research report on Tuesday, March 17th. Mizuho boosted their price objective on shares of Lantheus from $85.00 to $95.00 and gave the company an “outperform” rating in a research report on Monday, April 13th. Finally, Citizens Jmp boosted their price objective on shares of Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research report on Tuesday, February 24th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $88.86.

Lantheus Stock Up 1.0%

Shares of LNTH opened at $85.50 on Friday. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $108.91. The company has a market cap of $5.57 billion, a P/E ratio of 25.37 and a beta of -0.08. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.70 and a quick ratio of 2.51. The firm has a 50 day simple moving average of $78.85 and a two-hundred day simple moving average of $68.12.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.50. The company had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts forecast that Lantheus Holdings, Inc. will post 4.29 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.